Today: 18 May 2026
Google faces AI test after BofA’s $430 price target

Google faces AI test after BofA’s $430 price target

MOUNTAIN VIEW, California, May 18, 2026, 07:03 (PDT)

Bank of America is sticking with its Buy on Alphabet and holds its $430 target, with the focus turning to Tuesday’s Google I/O. Analyst Justin Post thinks the developer event will bring a raft of AI updates—Gemini tweaks, tighter integration, new agent features. He said the stock may need some “AI surprises” for further multiple expansion. TipRanks

Alphabet’s Class A shares traded up 1.3% at $401.87 during early Nasdaq action Monday. Class C shares added 1.2% to $398.20. The move put the company’s market value close to $4.9 trillion as investors watched for signs that spending on AI is driving revenue, not just costs.

This is why it’s in focus now. Google I/O kicks off Tuesday at 10 a.m. Pacific with a keynote. The company’s developer event is set to center on Search, Android, Gemini, and smart glasses—no formal financial updates on the agenda. It takes place at Shoreline Amphitheatre in Mountain View, with Google streaming sessions and keynotes online on May 19-20.

Alphabet starts the week showing better numbers than last year. First-quarter revenue climbed 22% to $109.9 billion, a filing showed. Google Cloud revenue was up 63% to $20.0 billion. CEO Sundar Pichai credited AI bets and a “full stack approach,” saying they were “lighting up every part of the business.” SEC

The key issue is whether the demos are good enough for the stock. Post’s team said expectations are elevated, and if there’s no “wow” factor, shares could take a hit. They flagged risks: lost search traffic to competing AI products, delays in rolling out large language models to search, pressure from the EU Digital Markets Act, and growing capital spending that could drag on free cash flow. TheStreet

Agentic AI looks set to be in focus, meaning products that act for users instead of only replying to prompts. According to Post, this could trigger new questions about direct traffic for travel, e-commerce, and delivery sites, but he still thinks broad use is years out, not quarters. Booking and Expedia may show up as travel partners, but Amazon probably won’t be an early e-commerce partner.

William Blair’s Ralph Schackart kept a Buy on Alphabet Class C, pointing to Google’s vertically integrated AI from research through apps and strong ROIC. Scotiabank is also staying at Buy with a $450 target, according to TipRanks.

Google Cloud is still trailing Amazon Web Services and Microsoft Azure, but saw 63% growth last quarter, outpacing both rivals’ most recent cloud numbers, Reuters reported. Google also started selling its Tensor Processing Units—custom AI chips designed to take on Nvidia’s graphics processors—as it pushes to sell more of its internal tech to outside buyers.

Alphabet upped its 2026 capital spending plans to between $180 billion and $190 billion, Reuters said, citing CFO Anat Ashkenazi. Ashkenazi also said there’s another big rise coming in 2027. Thomas Monteiro at Investing.com said it’s “well within the company’s spending power” after faster growth in cloud. Reuters

Sentiment is in focus, too. Bill Ackman said on Saturday that Pershing Square’s exit from Alphabet wasn’t a bearish move. He wrote the fund is “very bullish long term,” but needed to tap Google shares to raise cash for its position in Microsoft. Reuters

Tuesday’s focus is clear. Investors are looking for practical AI tools in Search and Android, proof that Gemini benefits Cloud and subscriptions, and reassurance that Alphabet’s big data-center and chip investments won’t hit margins hard. Bank of America’s $430 price target leaves Google some upside, but little space to disappoint.

Latest articles

Google faces AI test after BofA’s $430 price target

Google faces AI test after BofA’s $430 price target

18 May 2026
Alphabet shares rose over 1% Monday, valuing the company near $4.9 trillion ahead of Tuesday’s Google I/O developer conference in Mountain View. Bank of America and other analysts kept Buy ratings, citing strong AI and cloud growth, but warned that high expectations and lack of major AI announcements could pressure the stock. Google I/O will focus on Search, Android, Gemini, and smart glasses.
Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

18 May 2026
Quince Therapeutics was last quoted at $1.15 before Monday’s Nasdaq open after Nantahala Capital Management disclosed 7.52% beneficial ownership. The company’s latest filing reported no current product candidates and raised substantial doubt about its ability to continue as a going concern. Quince is seeking shareholder approval for another reverse stock split at its June 11 meeting. The company remains out of compliance with Nasdaq’s $50 million market value rule.
Macy’s Gains Pre-Market as Berkshire Buys In — What’s Ahead for Traders

Macy’s Gains Pre-Market as Berkshire Buys In — What’s Ahead for Traders

18 May 2026
Macy’s shares rose in premarket trading after Berkshire Hathaway disclosed a new stake of 3.04 million shares, valued at about $55 million as of March 31. The stock closed Friday at $18.41 and last traded at $18.99 premarket with 128,170 shares exchanged. Macy’s will report first-quarter results on June 3. Tariffs, fuel costs, and weak discretionary spending remain risks for the retailer.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

18 May 2026
ImmunityBio said Monday five U.S. patents protect its Anktiva-plus-BCG bladder cancer treatment through at least 2035, following an exclusive U.S. supply deal with Japan BCG Laboratory. The company plans to seek FDA approval for the Tokyo-172 BCG strain, which is not yet approved in the U.S. ImmunityBio shares last traded at $7.97 before the Nasdaq open.

Popular

Redwire Shares Up 27%, Focus Turns to Next Test Today

Redwire Shares Up 27%, Focus Turns to Next Test Today

18 May 2026
Redwire Corp shares held near $14.06 in premarket trading Monday after a 27% rally last week, as investors awaited updates from the SOF Week defense event in Tampa. The company reported a contracted backlog of $498.1 million at March 31 and first-quarter revenue of $97.0 million, but posted a net loss of $76.5 million. Redwire recently launched a $350 million at-the-market stock sale program.
Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing
Previous Story

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

Go toTop